Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Rating of “Buy” from Brokerages

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has earned an average recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $16.5556.

IVA has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Thursday, January 22nd. Barclays assumed coverage on Inventiva in a research note on Tuesday, January 27th. They set an “overweight” rating and a $18.00 target price for the company. Leerink Partners assumed coverage on Inventiva in a report on Monday, January 12th. They issued an “outperform” rating and a $12.00 target price for the company. UBS Group assumed coverage on Inventiva in a report on Wednesday, January 7th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Truist Financial assumed coverage on shares of Inventiva in a research report on Thursday. They set a “buy” rating and a $13.00 price objective for the company.

Institutional Investors Weigh In On Inventiva

A number of large investors have recently bought and sold shares of IVA. Paradigm Biocapital Advisors LP bought a new stake in Inventiva in the fourth quarter valued at $18,600,000. ADAR1 Capital Management LLC bought a new position in shares of Inventiva during the 4th quarter worth about $12,601,000. Millennium Management LLC grew its stake in shares of Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after buying an additional 2,540,540 shares during the period. UBS Group AG increased its position in Inventiva by 28,881.6% in the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after buying an additional 2,634,580 shares in the last quarter. Finally, SymBiosis Capital Partners LLC bought a new stake in Inventiva in the 4th quarter valued at about $12,090,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Stock Performance

IVA stock opened at $6.04 on Friday. The company’s fifty day simple moving average is $6.28 and its 200 day simple moving average is $5.36. Inventiva has a 12-month low of $2.70 and a 12-month high of $7.98.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.